Panacea Biotec Receives ₹10.23 Crore Income Tax Demand Order
Panacea Biotec received a ₹10.23 Crore Income Tax demand order for AY 2016-17 due to disallowed expenses. The company believes the demand is non-maintainable and plans to appeal, expecting no significant financial or operational impact.
A demand of ₹10.23 Crore, while assessed as non-impactful by the company, represents a material financial figure that could potentially affect the company if the legal recourse is unsuccessful. The company's assertion of no significant impact lessens it to medium.
The company received a significant tax demand, which is a negative development. However, the company's assessment that the demand is non-maintainable and their intention to appeal, coupled with the expectation of no significant impact, mitigates the negative sentiment to neutral.
Panacea Biotec Limited has received a Demand Order dated March 01, 2026, from the Office of the Deputy Commissioner of Income Tax, Central Circle 29, Delhi. The order, issued under Section 156 of the Income Tax Act, 1961, imposes a demand aggregating to approximately ₹10.23 Crore. This demand pertains to disallowances of certain expenditures related to the Assessment Year 2016-17.
The company was informed of this demand on March 06, 2026. The disallowances were made under Section 37 of the Income Tax Act due to the incorrect categorization of certain expenses, which were alleged to be in violation of Medical Council of India (MCI) Regulations.
Panacea Biotec assesses the demand as non-maintainable, stating it is misplaced as it does not account for the company's revised tax filings, which show no taxable income or tax liability due to brought-forward losses. The company is pursuing legal recourse, including filing a rectification application and an appeal. Panacea Biotec does not foresee any significant impact on its financial, operational, or other activities.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.